Audit: QRS - Phosphatidylethanolamine for Health & Longevity of the ER frontmatter

Audit conducted on 09/08/2026 19:46 using AI4L / Grok 4

Iterations

Summary

Items	Count
Total	91
Passed	84
Failed	0
N/A	7
Pass Rate	100.00%

• Total = Passed + Failed + N/A
• Pass Rate = Passed / (Passed + Failed) × 100
• N/A items are excluded from the pass rate calculation

---

1. General Rules

#	Description	Result	Comments
1.1	Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER.	🟢	Protocol, benefits, risks, gates, monitoring, and at-a-glance align with ER Protocol, Expected Benefits, Potential Risks, Key Interactions & Contraindications, Monitoring, and Conclusion.
1.2	Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing.	🟢	“Not established”, “theoretical”, “caution, theoretical”, and related hedges preserved.
1.3	The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”).	🟢	Stop/caution mapping tracks ER absolute vs caution language; safety wording matches food/typical lecithin scope.
1.4	The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc.	🟢	Interactions and population avoids drawn from Key Interactions & Contraindications; risks from Potential Risks; benefits from Expected Benefits.
1.5	PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact.	🟢	None of these appear in the QRS.
1.6	The QRS does not introduce new attributions.	🟢	No new attributions.

2. Focus, Tone & Audience

#	Description	Result	Comments
2.1	The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing.	🟢	Cautious, evidence-limited tone matches ER.
2.2	The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging	🟢	Neutral expert presentation appropriate for limited-evidence topic.
2.3	The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor	🟢	Presents distilled ER content without doctoring.
2.4	The QRS avoids language that implies medical or clinical advice	🟢	No prescribe/advise framing.
2.5	The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising”	🟢	Protocol and gates present ER facts.
2.6	The QRS never addresses “the reader” directly — it presents evidence, not guidance	🟢	No direct address.
2.7	The QRS is written in plain language, avoiding unnecessary medical jargon	🟢	At-a-glance plain; body uses ER terms (PC/PE, PEMT, ferroptosis) appropriate to longevity audience.
2.8	Information is presented in a concise and very compact manner	🟢	Condensed labels and semicolon-joined tier lists.
2.9	It DOES NOT address the reader directly	🟢	No you/your.
2.10	The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review.	🟢	Functional ranges, methyl donors, food-first framing.
2.11	The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort.	🟢	Dietary emphasis and multi-marker monitoring fit this audience.
2.12	The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort.	🟢	Not dumbed-down general-pop framing.
2.13	Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience.	🟢	Reflects limited PE-specific evidence with practical phospholipid/food approach.
2.14	The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim.	🟢	Uses longevity/healthspan; no anti-aging.
2.15	The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt.	🟢	Formal where needed; plain gloss in at-a-glance only.

3. Template Integrity

#	Description	Result	Comments
3.1	The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why”	🟢	All fixed labels present and unmodified.
3.2	All “…” from the [qrs_template] are present in the the QRS.	🟢	All template variables present (marker_# and qualitative_item_# expanded to concrete indices).
3.3	Spans that are not addressed in a checklist item are left unchanged	🟢	Website scaffolding spans and unaddressed structure retained; empty tiers/time slot only changed per checklist rules.

4. Formatting

#	Description	Result	Comments
4.1	When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied”	N/A	No source ER section is empty in the sense that requires empty-state phrasing; empty benefit/risk tiers handled by 12.5/13.5.
4.2	Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label.	🟢	Protocol action labels match ER bold labels (Dietary baseline; Lecithin / mixed phospholipid supplementation; Timing).
4.3	Labels are not paraphrased, abbreviated, or invented.	🟢	Protocol and interaction labels track ER; benefit/risk tier content condenses #### headings per 12.x/13.x.
4.4	The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels.	🟢	No emoji indicators in QRS body.
4.5	The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page.	🟢	Content condensed into single-sheet structure.

5. Metadata

#	Description	Result	Comments
5.1	The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content.	🟢	Immediate HTML comment after doctype.
5.2	Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML.	🟢	Standard — YAML — delimiters.
5.3	The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet.	🟢	Comment-only metadata.
5.4	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Values trimmed; duration quoted for colon.
5.5	The filename of the source ER is stated as “er_filename: [er_filename]”	🟢	er_filename: phosphatidylethanolamine_2026-0809-1806_Grok_ER.md
5.6	Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]”	🟢	qrs_prompt_version: 26.7.02
5.7	Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430)	🟢	qrs_creation_date: 2026-0809-1853
5.8	The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]”	🟢	qrs_creator_ai_nickname: Grok
5.9	The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT)	🟢	Grok
5.10	The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]”	🟢	qrs_creator_ai_fullname: Grok 4
5.11	The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4)	🟢	Grok 4
5.12	The filename of the document is stated as “qrs_filename: [filename of this document]”	🟢	qrs_filename: phosphatidylethanolamine_2026-0809-1806_Grok_QRS.html
5.13	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Consistent with 5.4.

6. Page Title & Header

#	Description	Result	Comments
6.1	[page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &)	🟢	Phosphatidylethanolamine for Health & Longevity - Quick Reference Sheet
6.2	[header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &)	🟢	Matches canonical_topic with &
6.3	[header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]	🟢	08/09/2026 from 2026-0809-1853
6.4	[header_subline_model] is set to [qrs_creator_ai_fullname]	🟢	Grok 4
6.5	No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker.	🟢	Only standard subline template content.

7. At-A-Glance Section

#	Description	Result	Comments
7.1	[at_a_glance] is dense, execution-oriented summary of the ER Conclusion section	🟢	Condenses membrane role, lack of human healthspan evidence for stand-alone PE, food/lecithin sources, and tolerability.
7.2	[at_a_glance] is no longer than 60 words	🟢	58 words.
7.3	Every fact in [at_a_glance] is supported by a distinct passage in the ER.	🟢	Supported by Conclusion and related biology/safety passages.
7.4	It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead	🟢	Full compound name; plain “cell-membrane fat”, “cellular recycling”; no PE/PC/PEMT.
7.5	It DOES NOT cite specific trials (names, years, sample sizes, p-values)	🟢	None.
7.6	It DOES NOT cite effect sizes, relative risks, or statistical results	🟢	None.

8. Contraindications

#	Description	Result	Comments
8.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	From populations who should avoid / absolute source allergy.
8.2	[stop_items] represent the Contraindications from the ER	🟢	Soy/egg allergy (absolute); purified high-dose PE in infants or pregnancy.
8.3	Individual [stop_items] are formatted as <li></li>	🟢	Two <li> items.
8.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	Concise; no trailing dash clauses.
8.5	Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	“(absolute for that source)” preserved.
8.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	ER stop-relevant content does not use ranking notation.
8.7	If no [stop_items] are present the section is left empty	N/A	stop_items are present.

9. Key Interactions

#	Description	Result	Comments
9.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	Interaction bullets plus population caution as appropriate.
9.2	[caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications	🟢	Five interaction bullets plus ferroptosis population caution (ER: not formal labeled contraindication); stop items excluded.
9.3	Individual [caution_items] are formatted as <li></li>	🟢	Six <li> items.
9.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	Dash-trailing clauses stripped (e.g., ferroptosis); key facts retained.
9.5	Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	Example drugs, monitor/caution tags, e.g. iron-overload syndromes preserved.
9.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	No ranking notation in interaction items.
9.7	If no [caution_items] are present the section is left empty	N/A	caution_items are present.

10. Protocol

#	Description	Result	Comments
10.1	The section is derived from the ER Protocol section	🟢	Dietary baseline, lecithin proxy, and timing from Therapeutic Protocol.
10.2	The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section	🟢	Food baseline, lecithin dosing, timing with meals.
10.3	If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	Three actionable aspects used.
10.4	All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section.	🟢	All three action triples filled from Protocol (and closely related Protocol co-nutrient notes for timing sub).

11. Time to Effect

#	Description	Result	Comments
11.1	The three sets of [time] items cover the three most important time-to-effect aspects from the ER	🟢	Two distinct TTE aspects from Practical Considerations (longevity/clinical; membrane remodeling).
11.2	The sets are picked and ordered by the magnitude of the related benefit	🟢	Longevity/clinical first, then membrane remodeling.
11.3	If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	🟢	time_3 empty with pcell display:none.
11.4	All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER.	🟢	time_1 and time_2 fully filled from ER.
11.5	If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel	N/A	ER Practical Considerations provides time-to-effect information.

12. Benefits

#	Description	Result	Comments
12.1	The section is derived from the ER Expected Benefits section	🟢	Low and Speculative headings condensed from ER.
12.2	Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]	🟢	All four spans present.
12.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Semicolon-joined key facts; mechanisms stripped.
12.4	Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	e.g., (preclinical), (PEMT pathway), via LC3–PE lipidation stripped.
12.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	🟢	benefits_high and benefits_medium use style=”display:none”.

13. Risks

#	Description	Result	Comments
13.1	The section is derived from the ER Potential Risks & Side Effects section	🟢	Low and Speculative risks from ER.
13.2	Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]	🟢	All four spans present.
13.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Key risk labels only.
13.4	Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	e.g., (soy lecithin) stripped from source-related contaminants.
13.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	🟢	risks_high and risks_medium use style=”display:none”.

14. Monitoring

#	Description	Result	Comments
14.1	The section is derived from the ER Monitoring section	🟢	From Monitoring Protocol & Defining Success.
14.2	All measurable/quantifiable biomarkers from the Monitoring section are listed	🟢	All 8 table biomarkers listed (ALT/AST through ferritin/iron studies).
14.3	[monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty.	🟢	Baseline + ~8–12 week recheck + 6–12 month cadence.

15. Qualitative Assessment

#	Description	Result	Comments
15.1	The section is derived from the ER Monitoring section	🟢	Qualitative markers from Monitoring.
15.2	All subjective/qualitative biomarkers from the Monitoring section are listed	🟢	All four qualitative markers listed verbatim.

Issues 09/08/2026 19:46

Pass rate 100.00%. No issues found.

Issues 09/08/2026 19:34

1. 1.3 — Neuroprotection claim strengthened: Speculative benefits list “Neuroprotection in Parkinson’s and Alzheimer’s”, dropping ER’s “PE-limited” and “models” and strengthening a model-only claim.

2. 11.1 — Distinct TTE aspects overstated: ER Practical Considerations gives two distinct time-to-effect facts (membrane remodeling over weeks; no human timeline for lifespan/clinical endpoints); QRS splits clinical vs longevity into two cells.

3. 11.2 — Time-to-effect order: Sets ordered membrane → clinical → longevity; by magnitude of related benefit, longevity/lifespan should rank ahead of membrane remodeling.

4. 11.3 — Third TTE cell should be empty: Only two distinct TTE aspects in the ER; the third time set is filled instead of left empty and invisible.

Fixes 09/08/2026 19:36

1. 1.3 — Neuroprotection claim scope: Restored ER scope in speculative benefits: “Neuroprotection in PE-limited Parkinson’s and Alzheimer’s models” (was shortened to drop PE-limited/models).

2. 11.1 / 11.3 — Two distinct TTE aspects: Merged clinical and longevity into one time cell; left time_3 empty and hidden (display:none) so only two distinct ER time-to-effect facts remain.

3. 11.2 — Time-to-effect order: Reordered by magnitude of related benefit: longevity/clinical endpoints first, then membrane remodeling (weeks).

Issues 09/08/2026 19:26

1. 12.3 — Benefit mechanism/study detail: Low/Speculative benefits keep mechanistic “via dietary phospholipids” and “via LC3–PE lipidation”, and study-context wording “in PE-limited Parkinson’s and Alzheimer’s models”, instead of bare key facts.

2. 13.3 — Risk mechanistic qualifier: Speculative risks keep “Homocysteine elevation via accelerated PEMT flux” rather than the bare key fact “Homocysteine elevation”.

Fixes 09/08/2026 19:27

1. 12.3 — Benefit mechanism/study detail: Stripped mechanistic “via dietary phospholipids” and “via LC3–PE lipidation” and study-context “PE-limited … models” from Low/Speculative benefits, leaving bare key facts.

2. 13.3 — Risk mechanistic qualifier: Shortened speculative risk from “Homocysteine elevation via accelerated PEMT flux” to “Homocysteine elevation”.

Issues 09/08/2026 19:16

1. 1.2 — Monitoring target hedging: Marker Target cells drop ER “aimed” language (ALT/AST, GGT, Homocysteine, Hs-CRP), so cautious “often aimed” phrasing is not preserved.
2. 1.3 — Strengthened functional targets: Same omission of “aimed” slightly strengthens aspirational functional ranges into firmer-looking cutoffs relative to the ER Monitoring table.
3. 8.4 — Pregnancy stop elaboration: Contraindication item “Purified high-dose PE supplements in infants or pregnancy (food sources remain the default)” retains a trailing elaboration that should be stripped for concision.

Fixes 09/08/2026 19:17

1. 1.2 / 1.3 — Monitoring target hedging: Restored ER “aimed” language in marker targets for ALT/AST, GGT, Homocysteine, and Hs-CRP (e.g., “Often ~<…” → “Often aimed ~<…”).
2. 8.4 — Pregnancy stop elaboration: Removed trailing elaboration “(food sources remain the default)” from the infants/pregnancy contraindication item.

Issues 09/08/2026 19:07

1. 1.2 / 1.3 — Lecithin dose “often” dropped: action_2_value gives “1,200–3,600 mg/day lecithin” without the ER Therapeutic Protocol qualifier “often”, strengthening a common consumer range into a fixed dose.
2. 9.5 — Interaction severity qualifiers: Key interaction items drop ER parenthetical severity classes—especially choline/methyl-donor “(monitor / potentiating)”, lecithin “(monitor)”, iron “caution” from “(caution, theoretical)”, and anticoagulants “(monitor for mixed phospholipids)”.

Fixes 09/08/2026 19:09

1. 1.2 / 1.3 — Lecithin dose qualifier restored: action_2_value changed from “1,200–3,600 mg/day lecithin” to “Often 1,200–3,600 mg/day lecithin” to match the ER’s cautious “often” phrasing.
2. 9.5 — Interaction severity qualifiers: Restored ER parenthetical severity classes on caution_items (monitor / potentiating; monitor; caution, theoretical; monitor for mixed phospholipids) while keeping concise key facts and example drugs.

Issues 09/08/2026 19:00

1. 1.2 — Cautious theoretical phrasing dropped: ER marks iron-overload and lipophilic-drug interactions as theoretical/mechanistic-only; QRS Key Interaction lines omit that cautious phrasing.

2. 4.2 — Protocol labels not verbatim: Action labels do not use the ER Protocol bold labels: QRS has “Lecithin proxy” and “Timing & cofactors” (and shortens “Dietary baseline (primary practical approach)”).

3. 4.3 — Protocol labels paraphrased: “Lecithin proxy” and “Timing & cofactors” are invented/abbreviated rather than ER labels.

4. 9.5 — Theoretical severity omitted: Parenthetical severity class “theoretical” from the ER iron and lipophilic interaction bullets is not preserved on the corresponding caution items.

Fixes 09/08/2026 19:03

1. 1.2 / 9.5 — Theoretical severity restored: Added “(theoretical)” to the iron-overload and lipophilic/narrow-therapeutic-index Key Interaction items to match ER cautious phrasing.

2. 4.2 / 4.3 — Protocol labels restored: Replaced paraphrased action labels with ER Protocol bold labels: “Dietary baseline (primary practical approach)”, “Lecithin / mixed phospholipid supplementation (common consumer proxy)”, and “Timing”.